Recently, the Ivonescimab Injection (trade name: 依达方) of Akeso Inc. is approved for marketing through the priority review and approval procedure by China NMPA. This product, in combination with pemetrexed and carboplatin, is indicated for the treatment of patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who are positive for EGFR gene mutation and have progressed after treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI).

As a humanized bispecific antibody of IgG1 subtype binding human vascular endothelial growth factor-A (VEGF-A) and programmed death protein-1 (PD-1), Ivonescimab Injection exerts anti-tumor activity by simultaneous binding to VEGF-A and PD-1 to competitively block the interaction of VEGF-A and PD-1 with their ligands. The marketing of this drug provides a new treatment option for patients.